BioCryst Pharmaceuticals(BCRX) - 2025 Q2 - Quarterly Results

—Company makes additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds of sale of European ORLADEYO business— RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. "The financial performance this quarter is the best in the company's history resulting from better-than-expected revenue growth and very ...